ReviewInternational journal of hepatology2025
Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies.
Review in International journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease.Frontiers in endocrinology · 2026Review
- Fibroblast Growth Factor 21 Analogues Improve Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis: An Updated Systematic Review and Meta-Analysis.International journal of hepatology · 2026Review
- Chitosan Nanoparticles for Natural Antioxidant Delivery in Metabolic Dysfunction-Associated Steatohepatitis Liver Disease (MASLD).International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic-associated steatotic liver disease (MASLD) is a burgeoning worldwide burden and is currently the leading indication for a liver transplant. Despite the growing burden of disease, there are few pharmacological treatments available. The underlying molecular mechanisms of the development of MASLD are still being elucidated. In this review, we will summarize the known molecular mechanisms in the development of MASLD along with past, current, and future pharmacologic clinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.